.-Surfactant protein (SP) D functions as a soluble pattern recognition molecule to mediate the clearance of pathogens by phagocytes in the innate immune response. We hypothesize that SP-D may also interact with dendritic cells, the most potent antigen presenting cell, to enhance uptake and presentation of bacterial antigens. Using mouse bone marrow-derived dendritic cells, we show that SP-D binds to immature dendritic cells in a dose-, carbohydrate-, and calcium-dependent manner, whereas SP-D binding to mature dendritic cells is reduced. SP-D also binds to Escherichia coli HB101 and enhances its association with dendritic cells. Additionally, SP-D enhances the antigen presentation of an ovalbumin fusion protein expressed in E. coli HB101 to ovalbumin-specific major histocompatibility complex class II T cell hybridomas. The enhancement of antigen presentation by SP-D is dose dependent and is not shared by other collectin-like proteins tested. These studies demonstrate that SP-D augments antigen presentation by dendritic cells and suggest that innate immune molecules such as SP-D may help initiate an adaptive immune response for the purpose of resolving an infection.
DENDRITIC CELLS (DCs) are bone marrow-derived antigen presenting cells (APCs) with the unique capacity to activate naive T cells and initiate immune responses. DCs residing in peripheral locations such as the lung and skin exist in an "immature" form that is capable of capturing antigen very efficiently by macropinocytosis (51) , endocytosis (51) , and phagocytosis (55) . Bacterial and inflammatory products stimulate the maturation of DCs, resulting in a downregulation of antigen uptake and an upregulation of T cell-stimulatory ability coincident with DC migration to regional lymph nodes (5) .
DCs are the most potent APC population in the lung, whereas resident macrophages are ineffective APCs because they suppress both DC function and T cell activation (23) . DCs in the lung are a rare population of cells found at all sites of antigen exposure, including the nasal mucosa, airway epithelium, lung parenchyma, and alveolar surface (37) . With an inflammatory stimulus such as bacterial exposure, the number of DCs at these sites greatly increases (19, 38) . Like other peripheral DCs, DCs isolated from the lung exist in an immature state in which they are competent for antigen uptake via receptor-mediated endocytosis but require additional signals for effective T cell activation (7, 54) . Recently, lung DCs have also been reported to be phagocytic (16) , although the mechanisms of microbial recognition and phagocytosis by lung DCs have not been investigated.
As sentinels of the immune system, DCs recognize and present microbial antigens to T cells. DCs have been shown to phagocytose a broad array of microorganisms (15, 24, 26, 29, 48) , resulting in the activation of antigen-specific T cells (42, 43, 55) . Microbial recognition is partly mediated by pattern recognition molecules expressed on DCs, although little is known about the mechanisms of phagocytic uptake (47) . Several studies (26, 27, 29, 48) have shown that preincubation of bacteria with serum enhances phagocytosis by DCs, suggesting that opsonization by serum molecules such as immunoglobulins or complement factors facilitates efficient bacterial uptake. Likewise, glycan receptors may be involved in DC phagocytosis because the uptake of zymosan is inhibited by mannan and ␤-glucan (48) . Other receptors involved in the uptake of particulate antigens by DCs include the fibronectin receptor (15) and the ␣ v ␤ 5 -integrin and scavenger receptor CD36 (1) .
Pulmonary surfactant protein (SP) A and SP-D are pattern recognition molecules that participate in the innate immune response against bacterial infection (61) . SP-A and SP-D as well as the serum proteins mannose binding lectin (MBL), conglutinin, and CL-43 are classified as collectins, a family of soluble pattern recognition molecules named for their NH 2 -terminal collagen-like domain and COOH-terminal lectin domain (14) . SP-A and SP-D are synthesized and secreted by alveolar type II and airway Clara cells into the liquid hypophase that covers the lung. In addition, a recent study (34) has demonstrated that mRNA for SP-D has been found in a variety of other mucosal tissues.
The pulmonary collectins participate in innate immunity with similar yet specialized functions. SP-A and SP-D act as opsonins to facilitate the removal of pathogens through interactions of their C-type lectin domain with carbohydrate and glycolipid structures on the surface of pathogens (9, 61) . Both lung collectins bind and aggregate several strains of bacteria, viruses, and allergens (9, 61) and interact with immune cells in a carbohydrate-and calcium-dependent manner (9, 61) . SP-A and SP-D enhance the phagocytosis of bacteria by both alveolar macrophages (49, 56, 60) and neutrophils (17) . The SPs also regulate other immune functions including chemotaxis, cytokine production, and T cell proliferation (4, 9, 11, 62) . Mice made deficient in SP-A and SP-D by targeted disruption of the genes are more susceptible to bacterial and viral infection (30) (31) (32) (33) and lipopolysaccharide (LPS)-mediated inflammation (3). Putative receptors for SP-A and SP-D [SPR-210 (6) and gp-340 (22) , respectively] have been described, although their contributions to many of the SP-mediated functions have not been confirmed. The SPs have also been reported to bind to the LPS receptor CD14 (52) .
The goal of the present study was to determine whether SPs enhance phagocytic uptake and presentation of microbes by DCs. We investigated whether SP-D was able to interact with a population of immature bone marrow-derived DCs (BMDCs) to enhance the phagocytosis and presentation of a bacterial model antigen, Escherichia coli HB101:Crl-OVA (45, 55) . We show that SP-D binds specifically to immature BMDCs, resulting in increased uptake of E. coli HB101 bacteria and enhanced antigen presentation of a defined ovalbumin (OVA) epitope expressed as a fusion protein in E. coli HB101. Our results indicate that SP-D augments an adaptive immune response against bacterial antigens, an important and previously unrecognized function for this innate pattern recognition molecule.
METHODS
Materials. Media, balanced salt solutions, antibiotics, and 2-mercaptoethanol were purchased from Life Technologies (Gaithersburg, MD). Fetal bovine serum and heat-inactivated fetal bovine serum were purchased from HyClone (Logan, UT). Agar and yeast extract for Luria broth agar plates were from Difco Laboratories (Detroit, MI). All other chemicals and reagents were obtained from Sigma (St. Louis, MO) except where noted.
Antibodies. Rat anti-mouse CD16/CD32 (Fc block), phycoerythrin (PE)-and fluorescein isothiocyanate (FITC)-conjugated mouse anti-mouse I-A b [major histocompatibility complex (MHC) class II], biotin-or FITC-conjugated rat antimouse Ly-6G (GR-1), FITC-conjugated hamster anti-mouse CD80 (B7-1), FITC-and PE-conjugated rat anti-mouse CD86 (B7-2), PE-conjugated hamster anti-mouse CD11c, and PEconjugated rat anti-mouse CD3 antibodies and all relevant isotype controls were purchased from PharMingen (San Diego, CA). FITC-conjugated rat anti-mouse macrophage clone F4180 was obtained from Caltag (Burlingame, CA), and FITC-conjugated rat anti-mouse CD4 was purchased from Life Technologies.
Generation of BMDCs. The DC isolation procedure was adapted from Inaba et al. (25) with some modifications. Bone marrow cells were flushed from the tibiae and femurs of 6-to 8-wk-old C57BL/6 (H-2b) mice (Charles River Laboratory, Raleigh, NC) and cultured in 24-well plates at 1 ϫ 10 6 cells/ml in DC medium [RPMI 1640 containing 5% heatinactivated fetal bovine serum (FBS), 100 U/ml of penicillinstreptomycin, 20 g/ml of gentamicin, and 50 M 2-mercaptoethanol] in the presence of granulocyte macrophage-colony stimulating factor [GM-CSF; 5% culture supernatant from X63 cells transfected with murine GM-CSF cDNA (provided by Dr. Chris Nicchitta, Duke University, Durham, NC), 20 ng/ml (kindly provided by Immunex, Seattle, WA), or 10 ng/ml (purchased from PharMingen)] for 6 days. The cells were washed on days 2 and 4 to remove nonadherent cells. Day 6 nonadherent cells were collected and purified further by negative selection with biotin-labeled anti-GR-1 followed by magnetic cell sorting (MACS) streptavidin beads (immature BMDCs; Miltenyi Biotec, Auburn CA). The cells were matured by reculture in 24-well plates at 3 ϫ 10 5 cells/ml in DC medium in the presence of 100 ng/ml of LPS or, in some cases, GM-CSF for 24 h. On day 7, the nonadherent cells were collected and used as mature BMDCs. Immature and mature cells were characterized for cell surface expression by flow cytometry. Immature cells were routinely GR-1 negative; CD80, CD86, and MHC class II low; and CD11c positive. Mature cells were routinely GR-1 negative, MHC class II high, and CD80, CD86, and CD11c positive.
Generation of OVA-specific T cell hybridomas. Two weeks before fusion, mice were immunized at the base of tail with 100 g of OVA antigen emulsified in complete Freund's adjuvant (CFA). Three days before fusion, draining periaortic and inguinal lymph nodes were harvested and cells were restimulated in vitro for 72 h at 37°C in 24-well plates at 4 ϫ 10 5 lymph node cells ⅐ 10 5 stimulators Ϫ1 ⅐ well Ϫ1 in a total volume of 1 ml of complete DMEM. Stimulators were prepared from splenocytes of nonimmunized mice and pulsed for 2 h at 37°C in 10 ml of complete DMEM with 100 g/ml of OVA 258-276 peptide. The pulsed stimulators were then washed, irradiated (3,000 rads), and resuspended in complete DMEM at 10 6 cell/ml for plating. On the day of fusion, in vitro restimulated T cells were washed with DMEM (without FCS or HEPES), counted, and mixed with BW5147 lymphoma cells in log growth at a 1:1 ratio, and fusion was performed as previously described (8) . Ten days after fusion, the wells were expanded and maintained in 1ϫ hypoxanthine-thymidine medium (Life Technologies) until sufficient growth had occurred to make duplicate cultures, at which time the cells were weaned to DMEM with 10% FCS. Hybridomas were screened by fluorescence-activated cell sorting (FACS) for expression of CD3 and CD4, and only clones expressing CD3 or CD3 and CD4 were subjected to further analysis. After screening for antigen specificity, hybridomas were cloned by limiting dilution (plated at 0.3 cells/well).
Hybridomas were screened for antigen specificity by determination of interleukin (IL)-2 secretion (mouse IL-2 mini-kit, Endogen, Woburn, MA) in response to a 24-h incubation at 37°C with syngeneic APCs and 100 g/ml of OVA peptide (2 ϫ 10 5 responders ⅐ 2 ϫ 10 5 stimulators Ϫ1 ⅐ well Ϫ1 in a total volume of 200 l in 96-well U-bottom plates).
Protein isolation and labeling. Recombinant rat SP-D was purified by maltose affinity chromatography from the medium supernatant of cultured Chinese hamster ovary cells expressing a full-length rat SP-D cDNA clone as previously described (12) . The SP-D preparations were tested for endotoxin and were found to have Ͻ5 pg endotoxin/g SP-D by the Limulus amebocyte lysate assay QCL-1000 (BioWhittaker, Walkersville, MD). SP-D was labeled with the Alexa Fluor 488 protein labeling kit (Molecular Probes, Eugene, OR) as described by the manufacturer, followed by dialysis into Dulbecco's PBS (D-PBS) to remove unbound label.
Human SP-A was purified from the bronchoalveolar lavage fluid of patients with alveolar proteinosis via butanol extraction as previously described (36) . SP-A was stored in 5 mM Tris, pH 7.4, at Ϫ20°C. The SP-A preparations were tested and treated for endotoxin and were found to have Ͻ5 pg endotoxin/g SP-A.
MBL was purified from rat serum (Pel-Freeze, Rogers, AR) by affinity and gel filtration chromatography as previously described (57) .
Human serum complement component 1q (C1q) was purchased from Advanced Research Technologies (San Diego, CA).
Bacteria. E. coli HB101 were transformed with a construct encoding an E. coli fusion protein containing the 257-277 epitope of OVA fused to the COOH terminus of crl, an E. coli gene that encodes a bacterial cytoplasmic protein that regulates curli surface organelle expression as previously described (45) . These bacteria, termed HB101:Crl-OVA, were stored as a 15% glycerol stock at Ϫ80°C and grown on Luria broth agar plates containing 100 g/ml of ampicillin for 16-18 h. Titers of bacteria were used to correlate the optical density of a bacterial suspension at 660 nm with colonyforming units per milliliter. Expression of the fusion protein was confirmed by SDS-PAGE and Coomassie blue staining of bacterial cell lysates. E. coli HB101:Crl-OVA were labeled with FITC (Molecular Probes, Eugene, OR) as previously described (49) . The bacteria were washed thoroughly to remove excess FITC label and were stored in 15% glycerol at Ϫ80°C.
SP-D binding. Immature BMDCs (2 ϫ 10 5 ) or, in some cases, BMDCs matured for 24 h in the presence of 100 ng/ml of LPS or GM-CSF were incubated with Alexa 488-labeled SP-D for 2 h on ice in a final volume of 0.1 ml of FACS buffer (D-PBS containing 1% BSA). For some studies, Alexa 488-labeled SP-D was heat treated at 95°C for 10 min before addition to the cells. For the carbohydrate inhibition studies, 10 mM maltose, 10 mM fucose, or 10 mM galactosamine were added at the beginning of the incubation. For calcium-dependent studies, D-PBS containing 0.9 mM calcium chloride or 1 mM EDTA was used. For the dual-binding studies, a PElabeled anti-CD86 antibody was added for the last 30 min of the incubation. Periodically, the cells were agitated to prevent settling of the cells. After incubation, the cells were washed two times by centrifugation at 4°C at 200 g and were then fixed in 1% paraformaldehyde. Binding of SP-D to the cells was assessed by FACS and is reported as the mean fluorescence of all the cells analyzed.
Uptake experiments. Immature BMDCs (2 ϫ 10 5 ) plated in a 96-well plate were incubated with FITC-labeled E. coli HB101:Crl-OVA at a bacteria-to-cell ratio of 100:1 in the presence and absence of SP-D (concentrations ranging from 0.5 to 7.5 g/ml) or the indicated concentrations of heattreated SP-D, SP-A, C1q, or MBL for 30 min at 37°C in the dark. The cells were collected, washed two times at 4°C at 200 g, and fixed in 1% paraformaldehyde. Association of bacteria with the BMDCs was analyzed by FACS and is reported as "relative fluorescence," which is defined as the percent mean fluorescence of all of the cells analyzed in the presence of added protein compared with the no-protein control.
Antigen presentation experiments. Antigen presentation experiments were performed as described by Svensson et al. (55) with some modifications. E. coli HB101:Crl-OVA bacteria were collected from 16-to 18-h overnight plate cultures grown on Luria broth-ampicillin and resuspended to 1 ϫ 10 9 colony-forming units/ml in PBS as determined by an optical density at 660 nm reading. Bacteria were added to 2 ϫ 10 5 immature BMDCs in a round-bottom 96-well plate at bacteria-to-cell ratios ranging from 5 to 100 in 0.1 ml of Iscove's modified Dulbecco's medium (IMDM) containing 10% heatinactivated FBS. In some cases, OVA protein, synthetic OVA 258-276 peptide, or E. coli HB101 not expressing the Crl-OVA fusion protein were added to the cells. SP-D and the other proteins tested were added at the indicated concentrations, and the plates were incubated at 37°C for 3 h. The cells were washed once with D-PBS, and then antigen uptake and processing were stopped by fixing the cells with 0.5% paraformaldehyde were then added at 1 ϫ 10 5 cells/0.1 ml IMDM containing 10% heat-inactivated FBS and antibiotics. After 24 h, the supernatants were collected, and an IL-2 ELISA assay was performed. Negligible IL-2 was produced when T cell hybridomas were incubated with BMDCs that were not exposed to antigen or when T cell hybridomas were incubated with OVA 258-276 peptide in the absence of prefixed BMDCs. The IL-2 levels produced varied between experiments probably due to differences between antigens and expression of the Crl-OVA protein as well as variation in CD3/CD4 expression of the T cell hybridomas and variation in the BMDCs from different cultures. In some experiments, data are reported as "relative IL-2 production," which is defined as the percent IL-2 produced in the presence of protein compared with the no-protein control.
SP-D-coated bacteria experiments. SP-D was preincubated with 6 ϫ 10 7 E. coli HB101:Crl-OVA in 0.3 ml of FACS buffer for 30 min at 37°C with shaking in the presence (SP-D-coated bacteria) and absence (noncoated bacteria) of SP-D at varying concentrations. The bacteria were washed two times and resuspended in IMDM without antibiotics before addition to BMDCs. For the appropriate conditions, SP-D was then added at varying concentrations to the noncoated bacteria. Cells were incubated for 3 h at 37°C and processed as described in Antigen presentation experiments.
FACS. FACS was performed at the Duke Comprehensive Cancer Center Flow Cytometry Facility. Samples (ϳ10,000 cells/treatment) were analyzed for fluorescence per cell at 514 nm after excitation at 488 nm.
Statistics. Data were compared by analysis of variance with Tukey's or Student's t-test where appropriate. Values were considered significant at P Ͻ 0.05.
RESULTS
Characterization of BMDCs. DCs isolated after 6 days of culture with GM-CSF consisted predominantly of immature DCs with a phenotype of CD11c
low , and CD86 low as described by others (25) (data not shown). After maturation of DCs for 24 h with LPS or GM-CSF, Ͼ60% of BMDCs routinely displayed a mature phenotype characterized by high expression of CD11c, MHC class II, CD80, and CD86, consistent with expected maturation, whereas the remaining cells exhibited a less mature phenotype (8) . The phenotype of BMDCs was also assessed by cytospin; mature DCs exhibited a typical stellate shape (25) (data not shown).
SP-D binds to immature BMDCs. SP-D bound to immature BMDCs in a calcium-dependent manner (Fig. 1A) , with up to 80% of the cell population positive for SP-D at 5 g/ml (data not shown). Binding of SP-D to immature BMDCs increased from 0.1 to 5 g/ml of SP-D (Fig. 1B) . As previously demonstrated with SP-D binding to leukocytes and epithelial cells (21, 28) , binding was completely inhibited by 1 mM EDTA at all doses tested. Binding was also dependent on the carbohydrate recognition domain of SP-D because binding was reduced by the addition of excess sugars known to compete for binding to SP-D (44) as well as by heat treatment of the protein (Table 1) .
We next compared the binding of SP-D to immature BMDCs and to BMDCs that were matured by culture with LPS or GM-CSF for 24 h. Figure 2A shows that the binding of SP-D to mature BMDCs stimulated with LPS or GM-CSF was reduced by 31 and 46%, respectively, compared with SP-D binding to immature BMDCs. To assess whether the reduced binding to the mature DCs correlated with the maturation state of the DCs, dual-binding studies were performed with an anti-CD86 antibody as a maturation marker. As expected, the percentage of cells expressing high levels of CD86 increased during culture with LPS or GM-CSF. Interestingly, the level of maturation induced by LPS and GM-CSF differed, although both stimuli induced the differentiation of cells expressing a high level of CD86. As indicated by FACS analysis, SP-D bound to the majority of immature, CD86
low BMDCs, whereas the proportion of cells low for SP-D binding increased with increasing expression of CD86 (Fig. 2B) . Compared with binding to immature cells, the mean fluorescence of the SP-D binding was reduced on all populations of BMDCs matured with either LPS or GM-CSF, with the most marked decrease observed on the most mature, high CD86-expressing cells. Similar results were seen with MHC class II as a maturation marker, although the data were not as clear-cut as with CD86 because the populations of low, intermediate, and high MHC class II cells were not as easily distinguishable as when CD86 was used as a maturation marker, particularly in experiments where overall maturation was lower (data not shown). Samples incubated with a single label were analyzed to exclude the effect of spectral overlap between the FITC and PE channels and to ensure that there was no interaction between the Alexa-labeled SP-D and the PE anti-CD86 antibody during the binding incubation (data not shown). Indeed, there was no difference in SP-D binding to the immature or mature BMDCs in the presence and absence of the dual label (data not shown).
Our initial studies employed a positive selection strategy for the isolation of DCs from GM-CSF-cultured mouse bone marrow cells with Miltenyi magnetic microbeads (MACS) against CD11c. However, we discovered that SP-D bound to the MACS beads used in the isolation. All of the studies reported here were done with cells purified by MACS-negative selection so that SP-D enhances the association of E. coli HB101 with immature BMDCs. SP-D has previously been shown (17, 49) to enhance the phagocytosis of gram-negative bacteria by both alveolar macrophages and neutrophils. Therefore, we tested the ability of SP-D to enhance the phagocytosis of the E. coli strain HB101 by BMDCs. SP-D enhanced the association of E. coli HB101 with BMDCs after a 30-min incubation with BMDCs and FITC-labeled E. coli HB101 (Fig. 3A) . As evidenced in the FACS plot in Fig. 3A , the effect of SP-D on bacterial association resulted in an increase in the fluorescence of the BMDCs rather than in an increase in the number of cells that were positive for the labeled bacteria, suggesting that SP-D mediates bacterial aggregation of E. coli HB101. Indeed, as assessed by a spectrophotometric aggregation assay, SP-D aggregated E. coli HB101 (data not shown). The enhancement by SP-D on bacterial association increased with increasing doses of SP-D from 0.5 to 5 g/ml, at which point the enhancement by SP-D reached a plateau (Fig.  3B) . Unfortunately, FITC-labeled E. coli HB101 could not be quenched by trypan blue (50) , and thus the data presented here depict total bacterial association with the BMDCs, including both binding and uptake of the bacteria to the BMDCs. Analysis of the cells by confocal microscopy confirmed that bacteria were indeed internalized (data not shown). 
SP-D enhances the antigen presentation of E. coli HB101:
Crl-OVA. E. coli HB101 expressing a fusion protein containing the 257-277 epitope of OVA (HB101:Crl-OVA) was used to assess the antigen presentation of the immunodominant OVA 258-276 epitope by BMDCs to an MHC class II-restricted T cell hybridoma. Because immature, but not mature, DCs are required to phagocytose particulate antigens for antigen presentation (1), immature BMDCs were incubated with E. coli HB101:Crl-OVA followed by fixation and several washes before the addition of T cell hybridomas. Figure 4A shows that in the absence of SP-D, the Crl-OVA antigen is presented in a dose-dependent manner, with IL-2 produced after exposure to as few as 1 ϫ 10 6 bacteria (a ratio of 5 bacteria to 1 BMDC). IL-2 production began to plateau from 1-2 ϫ 10 7 total bacteria (50-100 bacteria to BMDCs). This was not due to changes in the viability of the BMDCs in the presence of increasing doses of bacteria (data not shown). In the presence of 1 g/ml of SP-D, there was a consistent enhancement of the antigen presentation of E. coli HB101:Crl-OVA relative to the antigen presentation in the absence of SP-D at all bacterial concentrations (Fig. 4A) . The percent increase in IL-2 production due to the presence of SP-D at all bacterial concentrations is depicted in Fig. 4B .
As seen in Fig. 5 , SP-D enhanced the antigen presentation of E. coli HB101:Crl-OVA in a dose-dependent manner, with significant enhancement observed with as low as 0.1 g/ml of SP-D. The enhancement of antigen presentation increased with increasing doses of SP-D from 0.025 to 1 g/ml, at which point the enhancement by SP-D was maximal.
Incubation of DCs with E. coli HB101 not expressing the Crl-OVA construct did not result in antigen presentation as measured by IL-2 production (data not shown). Furthermore, there was virtually no presentation of E. coli HB101:Crl-OVA by mature DCs under all conditions tested (data not shown).
Enhancement of antigen presentation of E. coli HB101: Crl-OVA is specific to SP-D.
To examine whether the enhancement of E. coli HB101:Crl-OVA association and presentation was specific to SP-D, other members of the collectin family and the structurally homologous C1q were tested in experiments with BMDCs. Table 2 shows that, of the proteins tested, only SP-D significantly enhanced both bacterial association and antigen presentation, whereas enhancement was reduced by heat treatment of the protein. OVA protein or peptide was used in antigen presentation experiments. The data show that both OVA protein and peptide were presented by BMDCs to MHC class II T cell hybridomas in a dose-dependent manner. However, SP-D did not enhance the antigen presentation of OVA at any of the doses tested (Fig. 6A) , in contrast to its effects on E. coli HB101:Crl-OVA presentation. Likewise, SP-D did not enhance the antigen presentation of the OVA 258-276 peptide and statistically inhibited antigen presentation at 25 g/ml of peptide (Fig. 6B) . It is not clear whether this inhibition may have been due to SP-D binding to the peptide. Thus the SP-D-mediated enhancement of antigen presentation of E. coli HB101:Crl-OVA does not appear to be a direct effect of SP-D on BMDCs but may be due to its interaction with E. coli HB101.
SP-D binds E. coli HB101:
Crl-OVA and enhances antigen presentation. Both SP-A and SP-D have been shown to bind various pathogens to mediate phagocytosis by immune cells (17, 46) . The ability of SP-D to bind E. coli HB101 was tested by precoating the bacteria with SP-D and removing unbound SP-D before addition to the BMDCs. The data show that SP-D enhanced the antigen presentation of E. coli HB101: Crl-OVA with BMDCs to a greater extent when the bacteria were first coated with SP-D (Fig. 7A) . The enhancement by SP-D-coated bacteria on antigen presentation averaged 529 Ϯ 178.9% at 1 g/ml of SP-D compared with the no-protein control (data not shown) and was significantly greater than noncoated E. coli HB101 at SP-D concentrations of 0.1 g/ml and greater as assessed by a paired Student's t-test (P Ͻ 0.05; data not shown).
DISCUSSION
This study demonstrates that SP-D is able to interact with APCs to enhance the phagocytosis and antigen presentation of bacteria. We show that SP-D binds to a 
Values are means Ϯ SE; n ϭ 5-6 individual experiments for association and 3-6 individual experiments for antigen presentation. OVA, ovalbumin; IL, interleukin; ht SP-D, heat-treated SP-D; C1q, complement component 1q; MBL, mannose binding lectin; ND, not determined. Association experiments are described in Fig. 3 . Antigen presentation experiments are described in Fig. 4 . * P Ͻ 0.05 compared with no protein. population of immature BMDCs in a dose-, calcium-, and carbohydrate-dependent manner. Furthermore, SP-D binds to E. coli HB101 and augments its association with DCs, resulting in a dose-dependent enhancement of antigen presentation of an OVA fusion protein expressed in E. coli HB101. Although SP-D has previously been shown to enhance the phagocytosis of bacteria by immune cells (61) , this is the first study to demonstrate a linkage between the SP-D-mediated enhancement of phagocytosis and the resultant presentation of antigen, thus showing that SP-D is an important molecule in both the innate and adaptive immune responses.
The binding of SP-D to immature BMDCs and its reduced binding to mature BMDCs, identified by their increased expression of CD86, are consistent with the antigen-capturing functions of immature DCs and the finding that other pattern recognition molecules are also expressed at higher levels on immature than on mature DCs. For example, the mannose receptor is highly expressed on immature DCs where it is important in enhancing the internalization and antigen presentation of mannosylated antigens, whereas its expression on mature DCs is reduced by ϳ50% (13, 51) . Similarly, the Toll-like receptor-3 and scavenger receptor CD36 are more highly expressed on immature DCs than on cells matured in the presence of bacterial products or cytokines (1, 40) . gp-340 and CD14 have been identified as putative SP-D receptors (22, 52) . Although the expression and regulation of gp-340 on DCs are not known, it is unlikely that CD14 is the SP-D receptor on DCs because this molecule has been shown to be upregulated on DCs matured with LPS (35) .
Our studies demonstrate that SP-D increases T cell IL-2 production at a particular bacterial concentration by approximately fivefold when the bacteria are first coated with SP-D before addition to the BMDCs. Likewise, the efficiency of bacterial antigen presentation by BMDCs is increased in the presence of SP-D because fewer bacteria are required to achieve comparable antigen presentation compared with bacteria incubated in the absence of SP-D. This magnitude of enhancement of bacterial uptake and presentation by SP-D is similar to the reported effects of SP-D on the phagocytosis of viruses and bacteria by alveolar macrophages and neutrophils (17, 49) . The effect is also consistent with another study (48) Several lines of evidence indicate that the ability of SP-D to enhance the antigen uptake and presentation of E. coli HB101:Crl-OVA may be due to its direct interaction with bacteria. First, SP-D is unable to enhance the antigen presentation of the OVA protein or a synthetic OVA 258-276 peptide, suggesting that SP-D is not able to directly regulate components of the antigen processing and presentation pathway such as MHC class II peptide loading, MHC class II turnover, costimulatory molecules, or cytokines that would lead to an increased activation of T cells. However, we cannot exclude the possibility that SP-D may elicit changes in cell surface molecules or cytokine production that would affect T cell function under different experimental conditions such as longer incubation times. Furthermore, the T cell hybridomas used in this study are insensitive to the requirements of costimulation (8) Interestingly, all of the collectin-like proteins tested enhanced the association of E. coli HB101 with immature DCs, yet only SP-D stimulated significant enhancement of antigen presentation. An intriguing possible mechanism for the specific enhancement of antigen presentation by SP-D is that SP-D-mediated uptake of E. coli HB101 targets the bacteria to the antigen processing and presentation pathway, whereas the other proteins direct the uptake of the bacteria into an alternate pathway of the cell. Although little is known about the intracellular trafficking of SP-A and SP-D after cellular uptake, it is likely that differences in the cell surface receptors for these proteins may govern their traffic inside the cell. A study (53) has shown that enhanced antigen presentation by the B cell receptor and Fc receptor is linked to the existence of sequence motifs in the cytoplasmic domains of the receptors. These specialized motifs specify compart-ment localization of receptor-antigen complexes within the endocytic pathway through interactions with adaptor proteins and also initiate signaling cascades, resulting in accelerated movement to the antigen processing compartment. Likewise, it is possible that SP-A and SP-D may differentially regulate or interact with other components of the trafficking machinery.
However, there are a number of other reasons that may be equally plausible in explaining the lack of correlation between protein-mediated enhancement of bacterial association and enhancement of antigen presentation. First, in the association experiments, SP-A, C1q, and MBL enhanced the number of cells that were positive for labeled bacteria, whereas SP-D enhanced the number of bacteria associated with each positive cell as evidenced by the increase in the fluorescence of the positive cells. This finding supports the idea that SP-D is mediating the aggregation of E. coli HB101. Bacterial aggregation may result in enhanced antigen presentation by concentrating the bacteria in the antigen processing pathway after uptake by macropinocytosis or receptor-mediated endocytosis. Second, although experiments with the OVA peptide and protein suggest that SP-D is not maturing the DCs, it is possible that the interaction of SP-D with the bacteria alters its ability to activate host cells. This hypothesis is consistent with a recent study by Ofek et al. (41) demonstrating that SP-D enhances LPS-induced nitric oxide production in the presence of particulate LPS or bacteria but not in the presence of soluble LPS (41) . Third, labeling E. coli HB101 with FITC may have altered its interaction with the proteins in the association experiments compared with the antigen presentation experiments where unlabeled E. coli HB101 was used. Thus the association data may not accurately reproduce the uptake of the bacteria in the antigen presentation experiments. Finally, based on previous studies reviewed in Ref. 14 demonstrating that different collectins bind to and enhance phagocytosis of specific pathogens, we conjecture that the collectins may differentially function to enhance particulate antigen presentation and propose that studies on other pathogens may provide insight into the involvement of the other collectins in antigen presentation.
BMDCs were used in these studies due to the difficulty in purifying lung DCs. The in vitro culture systems used to generate BMDCs have been well described (25) and are useful because they allow the generation of large numbers of cells with very defined phenotypes for study. Likewise, a study (7) has shown that DCs freshly isolated from the lung share many of the same characteristics as those cultured in vitro. However, we cannot exclude the possibility that the interactions of SPs with lung DCs may differ compared with DCs derived from the bone marrow. Recent improvements have been made in the techniques used for isolating lung DCs such that it is possible to obtain pure populations of immature DCs without activating the cells during the isolation procedure (54, 58) . Thus future studies specifically on the interaction of surfactant with lung DCs may provide insight into the regulation of immune responses by the local milieu of the lung.
Previous studies (4, 59) have shown that SP-D inhibits the proliferation of T cells stimulated with mitogens. These studies and the present study considered together are consistent with the possibility that SP-D is able to both initiate an immune response and control inflammation against pathogens through the compartmentalization of the immune response. SP-D is found in the alveolar space of the lung where we postulate it is able to interact with immature DCs to enhance antigen uptake and processing and to interact with T cells to prevent their activation and protect the fragile lung epithelium against damaging inflammatory products. After antigen uptake, DCs mature and migrate to regional lymph nodes to activate T cells and initiate an immune response (20) . Thus the initiation of the immune response occurs in regional lymph nodes where no detectable mRNA has been found for SP-D (2). The studies described here address the ability of SP-D to interact with immature DCs, as may occur in the alveolar space, but do not address the interaction of SP-D with T cells because SP-D was incubated with the BMDCs in the antigen presentation experiments followed by fixation and several washes before the addition of the T cell hybridomas. The SP-D-mediated control of a compartmentalized immune response is intriguing and deserves further study.
In summary, these data identify a new role for SP-D in recognizing nonself-pathogens and initiating a protective immune response for their removal. It is tempting to speculate that the function of SP-D is not limited solely to E. coli HB101 and that SP-D may be able to enhance the antigen presentation of a broad range of pathogens including bacteria, viruses, and allergens that it recognizes as nonself. Likewise, the finding that message for SP-D exists in many mucosal tissues suggests that SP-D may function as a universal pattern recognition molecule able to regulate the immune response at all sites of pathogen invasion. A broader understanding of the role of SP-D in activating and regulating the adaptive immune response may provide a basis for the use of SP-D as a therapeutic agent to elicit an efficient immune response against a defined antigen.
